FDA panel votes 15-1-1 that Abbott's (ABT) Humira benefit is meaningful
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Join SI Premium – FREE
FDA panel votes 15-1-1 that Abbott's (NYSE: ABT) Humira benefit is meaningful. The panel also said Humira has benefit in UC after 8 weeks.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Amylyx's avexitide cuts hypoglycemia events 55% in Phase 3 trial
- Entera Bio names Riccardo Camisasca as chief medical officer
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
